Compare Stocks: CCCC, IMCR, FBRX, and TSHA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.39 -0.6%	$3.75	$1.69 ▼ $5.17	$417.05M	2.94	1.84 million shs	1.63 million shs
FBRX Forte Biosciences	$76.99	$71.39	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
IMCR Immunocore	$32.00 -0.9%	$34.68	$27.56 ▼ $40.71	$1.65B	0.74	329,650 shs	475,904 shs
TSHA Taysha Gene Therapies	$5.02 -2.7%	$5.79	$2.71 ▼ $7.30	$1.64B	1.19	2.55 million shs	9.12 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	0.00%	-3.42%	-15.88%	-17.92%	+0.30%
FBRX Forte Biosciences	0.00%	0.00%	+0.13%	+331.32%	+543.73%
IMCR Immunocore	0.00%	-1.84%	-11.80%	+11.89%	-4.25%
TSHA Taysha Gene Therapies	0.00%	0.00%	-17.84%	-21.81%	+73.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.39 -0.6%	$3.75	$1.69 ▼ $5.17	$417.05M	2.94	1.84 million shs	1.63 million shs
FBRX Forte Biosciences	$76.99	$71.39	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
IMCR Immunocore	$32.00 -0.9%	$34.68	$27.56 ▼ $40.71	$1.65B	0.74	329,650 shs	475,904 shs
TSHA Taysha Gene Therapies	$5.02 -2.7%	$5.79	$2.71 ▼ $7.30	$1.64B	1.19	2.55 million shs	9.12 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	0.00%	-3.42%	-15.88%	-17.92%	+0.30%
FBRX Forte Biosciences	0.00%	0.00%	+0.13%	+331.32%	+543.73%
IMCR Immunocore	0.00%	-1.84%	-11.80%	+11.89%	-4.25%
TSHA Taysha Gene Therapies	0.00%	0.00%	-17.84%	-21.81%	+73.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	126.16% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
IMCR Immunocore	2.58	Moderate Buy	$56.38	76.17% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	154.37% Upside

Current Analyst Ratings Breakdown

Latest CCCC, IMCR, FBRX, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/3/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$43.00
8/5/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	IMCR Immunocore	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$34.00 ➝ $35.00
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.95M	11.60	N/A	N/A	$2.65 per share	1.28
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
IMCR Immunocore	$400.02M	4.12	N/A	N/A	$7.52 per share	4.26
TSHA Taysha Gene Therapies	$9.77M	167.42	N/A	N/A	$0.90 per share	5.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	128.00	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest CCCC, IMCR, FBRX, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.45	5.45
FBRX Forte Biosciences	N/A	10.01	10.01
IMCR Immunocore	0.94	4.47	4.44
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
FBRX Forte Biosciences	77.63%
IMCR Immunocore	84.50%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	5.60%
FBRX Forte Biosciences	4.40%
IMCR Immunocore	10.10%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	104	123.03 million	116.14 million	Optionable
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
IMCR Immunocore	524	51.50 million	46.30 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

CCCC, IMCR, FBRX, and TSHA Headlines

Recent News About These Companies

Wolfe Research Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)

September 19 at 1:54 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17 at 9:05 AM | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Analysts

September 17 at 3:46 AM | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

September 12, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7, 2026 | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

August 26, 2026 | marketbeat.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, IMCR, FBRX, and TSHA Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$3.39 -0.02 (-0.59%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.01 (+0.35%)

As of 09/18/2026 07:30 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Immunocore NASDAQ:IMCR

$32.00 -0.30 (-0.93%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$31.83 -0.17 (-0.53%)

As of 09/18/2026 07:30 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Taysha Gene Therapies NASDAQ:TSHA

$5.02 -0.14 (-2.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.02 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, IMCR, FBRX, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, IMCR, FBRX, and TSHA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, IMCR, FBRX, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, IMCR, FBRX, and TSHA Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Forte Biosciences NASDAQ:FBRX

Immunocore NASDAQ:IMCR

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, IMCR, FBRX, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, IMCR, FBRX, and TSHA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, IMCR, FBRX, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, IMCR, FBRX, and TSHA Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Forte Biosciences NASDAQ:FBRX

Immunocore NASDAQ:IMCR

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools